Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.
Verkleij CPM, Frerichs KA, Broekmans MEC, Duetz C, O'Neill CA, Bruins WSC, Homan-Weert PM, Minnema MC, Levin MD, Broijl A, Bos GMJ, Kersten MJ, Klein SK, Shikhagaie MM, Casneuf T, Abraham Y, Smets T, Vanhoof G, Cortes-Selva D, van Steenbergen L, Ramos E, Verona RI, Krevvata M, Sonneveld P, Zweegman S, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: frerichs ka. Hemasphere. 2023 May 2;7(5):e881. doi: 10.1097/HS9.0000000000000881. eCollection 2023 May. Hemasphere. 2023. PMID: 37153876 Free PMC article.
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ. Frerichs KA, et al. Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Expert Rev Clin Immunol. 2018. PMID: 29465271 Review.
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.
Frerichs KA, Bosman PWC, van Velzen JF, Fraaij PLA, Koopmans MPG, Rimmelzwaan GF, Nijhof IS, Bloem AC, Mutis T, Zweegman S, van de Donk NWCJ. Frerichs KA, et al. Haematologica. 2020 Jun;105(6):e302-e306. doi: 10.3324/haematol.2019.231860. Epub 2019 Sep 26. Haematologica. 2020. PMID: 31558675 Free PMC article. No abstract available.
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC 3rd, Mutis T, van de Donk NWCJ. Frerichs KA, et al. Clin Cancer Res. 2020 May 1;26(9):2203-2215. doi: 10.1158/1078-0432.CCR-19-2299. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969333
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma.
Zajec M, Frerichs KA, van Duijn MM, Nijhof IS, Stege CAM, Avet-Loiseau H, Luider TM, de Rijke YB, Jacobs JFM, van de Donk NWCJ. Zajec M, et al. Among authors: frerichs ka. Hemasphere. 2020 Jul 15;4(4):e413. doi: 10.1097/HS9.0000000000000413. eCollection 2020 Aug. Hemasphere. 2020. PMID: 32904033 Free PMC article. No abstract available.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: frerichs ka. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
20 results